NRx Pharmaceuticals Management

Management Kriterienprüfungen 3/4

NRx Pharmaceuticals' CEO ist Steve Willard , ernannt in Jul 2022, hat eine Amtszeit von 2.08 Jahren. Die jährliche Gesamtvergütung beträgt $500.00K , bestehend aus 100% Gehalt und 0% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.98% der Aktien des Unternehmens, im Wert von $240.45K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.1 Jahre bzw. 2.1 Jahre.

Wichtige Informationen

Steve Willard

Geschäftsführender

US$500.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	100.0%
Amtszeit als Geschäftsführer	2.2yrs
Eigentum des Geschäftsführers	1.0%
Durchschnittliche Amtszeit des Managements	2.2yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	1.5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Steve Willard im Vergleich zu den Einnahmen von NRx Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	US$500k	US$500k	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$234k	-US$40m

Vergütung im Vergleich zum Markt: SteveDie Gesamtvergütung ($USD500.00K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: SteveDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Steve Willard (63 yo)

2.2yrs

Amtszeit

US$500,000

Vergütung

Mr. Stephen H. Willard, also known as Steve, Esq. serves as Acting Corporate Secretary at NRx Pharmaceuticals, Inc. He serves as Chief Executive Officer and Director at NRx Pharmaceuticals, Inc. since July...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	13.82% $ 2.6m
Stephen Willard	Acting Corporate Secretary	2.2yrs	US$500.00k	0.98% $ 183.7k
Richard Narido	CFO & Treasurer	less than a year	US$298.02k	0% $ 0
Riccardo Panicucci	Chief Manufacturing & Technology Officer	3.7yrs	US$240.00k	keine Daten
Suzanne Messere	Investor Relations	no data	keine Daten	keine Daten
Philip Lavin	Chief Methodologist	no data	keine Daten	keine Daten
Matthew Duffy	Chief Business Officer	1.5yrs	keine Daten	keine Daten

2.2yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrenes Management: NRXPDas Führungsteam des Unternehmens gilt als erfahren (2 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jonathan Javitt	Co-Founder	less than a year	US$630.20k	13.82% $ 2.6m
Stephen Willard	Acting Corporate Secretary	2.2yrs	US$500.00k	0.98% $ 183.7k
Chaim Hurvitz	Independent Director	3.3yrs	US$52.50k	2.07% $ 387.6k
Patrick Flynn	Independent Director	3.3yrs	US$67.50k	0.55% $ 103.3k
Janet Rehnquist	Independent Director	less than a year	keine Daten	keine Daten
Dennis McBride	Independent Director	less than a year	keine Daten	keine Daten

1.5yrs

Durchschnittliche Betriebszugehörigkeit

66.5yo

Durchschnittliches Alter

Erfahrener Vorstand: NRXPDie Vorstandsmitglieder gelten nicht als erfahren ( 1.9 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

NRx Pharmaceuticals Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

Recent updates

NRx Pharmaceuticals, Inc., Annual General Meeting, Oct 08, 2024

NRx Pharmaceuticals, Inc. Announces Resignation of Stephen Willard as Chief Executive Officer

NRx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 14, 2024

NRx Pharmaceuticals Receives Letter from the Listing Qualifications Staff of the Nasdaq Regarding Market Value of Listed Securities

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Announce Alignment with FDA on Pediatric Study Plan for NRX-100 (ketamine)

NRx Pharmaceuticals, Inc. to Proceed with Two New Drug Applications in 2024

NRx Pharmaceuticals, Inc. Appoints Dennis McBride to Its Board of Directors

NRx Pharmaceuticals, Inc. Presents Landmark Trial of Nrx-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: Nrx-101 Is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar Depression

NRx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

NRx Pharmaceuticals, Inc. Announces Final Clinical Trial Results

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. Announces Promising Findings in Phase 2B/3 Clinical Trial of Nrx-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.0031 million.

NRx Pharmaceuticals Demonstrates Compliance with the Nasdaq Bid Price Requirement in Listing Rule 5550(a)(2)

NRx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

New major risk - Share price stability

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

Price target increased by 7.1% to US$3.75

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

New major risk - Financial position

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

Co-Founder recently bought US$64k worth of stock

New major risk - Share price stability

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.285501 million.

Price target increased by 7.7% to US$3.50

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

CEO & Director recently bought US$59k worth of stock

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Independent Director recently bought US$515k worth of stock

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter